Results 31 to 40 of about 5,866 (194)

A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin’s lymphoma receiving chemotherapy

Haematologica, 2008
Background Growth factors are frequently used to aid peripheral blood progenitor cell mobilization from bone marrow. This phase 2 study examined the efficacy and safety of pegfilgrastim for mobilizing peripheral blood progenitors cells for autologous ...
Nigel Russell, Rolf Mesters, Joerg Schubert, Marc Boogaerts, Hans E. Johnsen, Consuelo del Canizo, Nigel Baker, Philippa Barker, Tomas Skacel, Norbert Schmitz   +9 more
doaj   +1 more source

Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review [PDF]

, 2016
The adoption of primary (PP) versus secondary prophylaxis (SP) of febrile neutropenia (FN), with granulocyte colony-stimulating factors (G-CSF), for adjuvant chemotherapy (AC) regimens in breast cancer (BC) could be affected by its “value for money ...
A Briggs, C Skedgel, C. Skedgel, CJ Murray, D Greenberg, D. Rayson, E Marseille, EK Lee, GH Lyman, GH Lyman, H Mason, H Roche, J Crawford, J Naurois De, JL Yu, KL Cooper, M Aapro, M Martin, MS Aapro, N Lathia, NM Kuderer, P Renner, P Trueman, S Whyte, S. Jovanovic, SD Ramsey, SE Jones, SS Rajan, T Younis, T. Younis, TJ Smith, YC Shih   +31 more
core   +1 more source

A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy‐induced neutropenia in patients with early‐stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study

Cancer Medicine, 2020
Eflapegrastim (Rolontis®) is a novel, long‐acting hematopoietic growth factor consisting of a recombinant human granulocyte‐colony stimulating factor (rhG‐CSF) analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker.
Patrick Wayne Cobb, Yong Wha Moon, Klára Mezei, István Láng, Gajanan Bhat, Shanta Chawla, Steven J. Hasal, Lee S. Schwartzberg   +7 more
doaj   +1 more source

Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. [PDF]

, 2006
peer reviewedIn order to assess the effect of Pegfilgrastim on the duration of neutropenia and clinical outcome of patients after autologous peripheral blood stem cell (PBSC) transplantation, we compared 20 consecutive patients with lymphoma or multiple ...
Beguin, Yves, Fillet, Georges, Frere, Pascale, Ngirabacu, Marie-Christine, Vanstraelen, Gaetan, Willems, Evelyne   +5 more
core   +1 more source

A randomized, non-inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus daily filgrastim in pediatric patients after autologous peripheral blood stem cell transplant. [PDF]

PLoS ONE, 2013
PurposeTo assess the non-inferiority of pegfilgrastim versus filgrastim in speeding the recovery of polymorphonuclear cells (PMN) in pediatric patients who underwent autologous peripheral blood stem cell transplant (PBSCT).MethodsThe sample size of this ...
Simone Cesaro, Francesca Nesi, Gloria Tridello, Massimo Abate, Irene Sara Panizzolo, Rita Balter, Elisabetta Calore   +6 more
doaj   +1 more source

82: Severe Hemorrhagic Cystitis (HC) After Allogeneic Hematopoeitic Stem Cell Transplantation (HSCT): Incidence and Risk Factors [PDF]

, 2008
With the purpose to investigate the radio emission of new ultracool objects, we carried out a targeted search in the recently discovered system VHS J125601.92$-$125723.9 (hereafter VHS 1256$-$1257); this system is composed by an equal-mass M7.5 binary ...
Azulay, R., Climent, J., Gauza, B., Guirado, J., Pérez-Torres, M., Rebolo, R., Zapatero Osorio, M.   +6 more
core   +2 more sources

Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051

Scientific Reports
Ramucirumab plus docetaxel (RD) can cause febrile neutropenia (FN), which frequently requires the prophylactic administration of pegfilgrastim. However, the effects of prophylactic pegfilgrastim on FN prevention, therapeutic efficacy, and prognosis after
Keita Miura, Ou Yamaguchi, Keita Mori, Atsushi Nakamura, Motohiro Tamiya, Tomohiro Oba, Noriko Yanagitani, Hideaki Mizutani, Takashi Ninomiya, Tomosue Kajiwara, Kentaro Ito, Akihiko Miyanaga, Daisuke Arai, Hiroaki Kodama, Kunihiko Kobayashi, Kyoichi Kaira   +15 more
doaj   +1 more source

Acute abdomen due to spontaneous splenic rupture as the first presentation of lung malignancy: a case report [PDF]

, 2011
Introduction Spontaneous splenic rupture is well recognized in the context of hematological malignancies (lymphoproliferative and myeloproliferative disorders); a few case reports have also linked solid tumors, such as pancreatic and liver ...
Angelos Kyriacou, Nolan Arulraj, Haren Varia   +2 more
core   +1 more source

Biopharmaceuticals for Cancer Treatment: An Update

Cancer Medicine, Volume 15, Issue 4, April 2026.
ABSTRACT Cancer is one of the most debilitating diseases, causing profound physical and psychological impacts on patients. The global number of cancer patients has been steadily rising over the last few decades. The development of effective cancer therapies remains the primary focus in life science research, requiring a precise understanding of ...
Anupom Deb Nath, Yousuf Alam, Afsana Mustak Mim, Maksuda Akter, Mohammad Abbas Gani, Khondaker Muhammad Khairul Alam, Md. Nur Alam   +6 more
wiley   +1 more source

Health professionals’ preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia

BMC Health Services Research, 2023
Background Febrile neutropenia associated with some chemotherapy regimens can lead to potentially fatal complications and high health care costs. Administration of pegfilgrastim using an On-Body Injector (OBI) may be more convenient for cancer patients ...
María Alejandra Larrarte-González, Mariana Pineda-Posada, Álvaro Andrés Gaitán, Jenny Amaya-Amaya, Kelman Ojeda   +4 more
doaj   +1 more source